IDEAYA Biosciences, Inc. (IDYA) has entered into a clinical study collaboration and supply agreement with Gilead Sciences, Inc. to evaluate the efficacy and safety of IDE397, its investigational small molecule MAT2A inhibitor, in combination with Gilead's Trodelvy, a Trop-2 directed antibody-drug conjugate, in a Phase 1 trial for treatment of MTAP-Deletion Bladder Cancer.